Idanna Innocenti

Idanna Innocenti

Auto-generated profile, based on publicly available information

Idanna Innocenti

Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2022 in British Journal of Haematology
Verified
Journal Article
Open access
EGEugenio Galli
Eugenio Galli
FSFedarica Sora
Fedarica Sora
SHStefan Hohaus
Stefan Hohaus
Alberto FresaAlberto Fresa
Alberto Fresa
IPIlaria Pansini
Ilaria Pansini
SSSimona Sica
Simona Sica
Summary: Cytokine release syndrome (CRS) and consumptive coagulopathy can complicate the treatment with chimeric antigen receptor T (CAR‐T) cells. The modified version of the Endothelial Activation and Stress Index (mEASIX), a score derived from haematopoietic stem cell transplantation, combines platelets, C‐reactive protein (CRP), and lactate dehydrogenase (LDH) and has been correlated with CRS and endothelial biomarkers. In 38 consecutive patients with aggressive lymphoproliferative disease we measured a coagulative laboratory panel at baseline and early after infusion of anti‐CD19 CAR‐T. The panel was investigated also in the presence of CRS graded 2 or higher, or immune effector cell‐associated neurotoxicity syndrome (ICANS). Moreover, we examined the relationship between mEASIX, coagulation biomarkers, and toxicities of CAR‐T cells. During CRS grade 2 or higher, we found increased prothrombin time (PT) and activated partial thromboplastin time (aPTT), fibrinogen, D‐dimer, factor VIII (FVIII), and von Willebrand factor (vWF) antigen levels, and decreased platelet count and antithrombin levels. The occurrence of immune effector cell‐associated neurotoxicity syndrome was associated with higher PT values, D‐dimer, FVIII, and vWF levels, and decreased fibrinogen levels and platelet count. A higher mEASIX score correlated with increased aPTT values, fibrinogen, D‐dimer, FVIII and vWF levels, and decreased antithrombin levels. Baseline mEASIX was predictive for consumptive coagulopathy and CRS graded 2 or higher, and for progression‐free survival and overall survival.

25 July 2023 in European Journal of Haematology
Verified
Journal Article
Open access
EGEugenio Galli
Eugenio Galli
Alberto FresaAlberto Fresa
Alberto Fresa
SBSilvia Bellesi
Silvia Bellesi
EMElisabetta Metafuni
Elisabetta Metafuni
EMElena Maiolo
Elena Maiolo
FSFedarica Sora
Fedarica Sora
Impaired function of hematopoiesis after treatment with chimeric antigen T‐cells (CAR‐T) is a frequent finding and can interest a wide range of patients, regardless of age and underlying disease. Trilinear cytopenias, as well as hypogammaglobulinemia, B‐cell aplasia, and T‐cell impairment, can severely affect the infectious risk of CAR‐T recipients, as well as their quality of life. In this review, we provide an overview of defects in hematopoiesis after CAR‐T, starting with a summary of different definitions and thresholds. We then move to summarize the main pathogenetic mechanisms of cytopenias, and we offer insight into cytomorphological aspects, the role of clonal hematopoiesis, and the risk of secondary myeloid malignancies. Subsequently, we expose the major findings and reports on T‐cell and B‐cell quantitative and functional impairment after CAR‐T. Finally, we provide an overview of current recommendations and leading experiences regarding the management of cytopenias and defective B‐ and T‐cell function.


2 February 2022 in Hematological Oncology
Verified
Journal Article
Open access
PDF file
IIIdanna Innocenti
Idanna Innocenti
ATAnnamaria Tomasso
Annamaria Tomasso
GBGiulia Benintende
Giulia Benintende
FAFrancesco Autore
Francesco Autore
Alberto FresaAlberto Fresa
Alberto Fresa
LLLuca Laurenti
Luca Laurenti
Secondary antibody deficiency (SAD) is a frequent manifestation of chronic lymphocytic leukemia (CLL) that increases the risk of infections. However, no formal guideline are available regarding the eligibility for prophylaxis or the delivery method, dosage, frequency of administration and duration of immunoglobulin replacement therapy (IgRT). The aim of this study was to assess the efficacy and safety of subcutaneous IgRT (SCIg) and its impact on quality of life (QoL) of CLL pts in the Covid‐19 era. Ten CLL pts with SAD were treated with subcutaneous IgRT (SCIg) at our institution between October 2019 and December 2020. Median age was 66 years and five patients had comorbidities. Seven patients were receiving therapy for CLL when treatment with SCIg was initiated. All pts received 10 g total dose hyaluronidase‐free SCIg independently from body weight. The IgG level and CD4/CD8, CD19 and CD16/56 lymphocytes subset were recorded at baseline and every 3 months. No patient experienced infectious events nor Covid‐19 mediated interstitial pneumonia while on SCIg therapy. All patients tolerated well the therapy and experienced an increase of IgG levels, which was then stable in time. We conclude that SCIg administration in CLL pts with SAD is efficacious and safe as infectious prophylaxis. This route of administration appears particularly advantageous in the Covid‐19 era, because of the self‐administration at home which results in improvement in the QoL and reduced treatment expenditures.

8 March 2022 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
EGEugenio Galli
Eugenio Galli
FSFedarica Sora
Fedarica Sora
SHStefan Hohaus
Stefan Hohaus
SBSilvia Bellesi
Silvia Bellesi
FAFrancesco Autore
Francesco Autore
SSSimona Sica
Simona Sica

5 July 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
Alberto FresaAlberto Fresa
Alberto Fresa
FAFrancesco Autore
Francesco Autore
APAlfonso Piciocchi
Alfonso Piciocchi
GCGioacchino Catania
Gioacchino Catania
Andrea VisentinAndrea Visentin
Andrea Visentin
LLLuca Laurenti
Luca Laurenti